Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

2.270 +0.020 (+0.89%)
Streaming Delayed Price Updated: 9:39 AM EDT, Mar 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,594
Open 2.260
Bid (Size) 2.260 (1)
Ask (Size) 2.280 (5)
Prev. Close 2.250
Today's Range 2.240 - 2.270
52wk Range 0.8214 - 2.760
Shares Outstanding 73,633,583
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. 
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga

Performance

YTD
+15.2%
+15.2%
1 Month
-9.9%
-9.9%
3 Month
+32.7%
+32.7%
6 Month
+108.3%
+108.3%
1 Year
+74.6%
+74.6%

More News

Read More
Earnings Outlook For Protalix BioTherapeutics
Via Benzinga
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Earnings Preview: Protalix BioTherapeutics
Via Benzinga
Earnings Scheduled For November 6, 2023
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
From Virtual Investor Conferences
Via GlobeNewswire
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Preview: Protalix BioTherapeutics's Earnings
Via Benzinga
Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
Via Benzinga
Earnings Preview For Protalix BioTherapeutics
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 14, 2024
Via Benzinga
Pullix Gains Momentum As Gamestop Exits NFT Space
Via Talk Markets
Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
Via Benzinga
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga

Frequently Asked Questions

Is Protalix BioTherapeutics, Inc. (DE) Common Stock publicly traded?
Yes, Protalix BioTherapeutics, Inc. (DE) Common Stock is publicly traded.
What exchange does Protalix BioTherapeutics, Inc. (DE) Common Stock trade on?
Protalix BioTherapeutics, Inc. (DE) Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Protalix BioTherapeutics, Inc. (DE) Common Stock?
The ticker symbol for Protalix BioTherapeutics, Inc. (DE) Common Stock is PLX on the New York Stock Exchange
What is the current price of Protalix BioTherapeutics, Inc. (DE) Common Stock?
The current price of Protalix BioTherapeutics, Inc. (DE) Common Stock is 2.270
When was Protalix BioTherapeutics, Inc. (DE) Common Stock last traded?
The last trade of Protalix BioTherapeutics, Inc. (DE) Common Stock was at 03/20/25 09:39 AM ET
What is the market capitalization of Protalix BioTherapeutics, Inc. (DE) Common Stock?
The market capitalization of Protalix BioTherapeutics, Inc. (DE) Common Stock is 167.15M
How many shares of Protalix BioTherapeutics, Inc. (DE) Common Stock are outstanding?
Protalix BioTherapeutics, Inc. (DE) Common Stock has 167M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.